Molecular prevalence and factors associated with infection in dogs from the North Pantanal wetland, Brazil.

Background And Aim: Canine monocytic ehrlichiosis is a vector-borne disease caused by the obligatory intracellular bacterium , which is distributed across tropical and subtropical regions worldwide. Its prevalence within dog populations is high in municipalities located across the Pantanal biome, but it remains unknown in Barão de Melgaço, Mato Grosso, Brazil. This study aimed to determine the molecular prevalence and factors associated with infection in dogs domiciled in Barão de Melgaço.

Comparative study of the use of miltefosine, miltefosine plus allopurinol, and allopurinol in dogs with visceral leishmaniasis.

Visceral leishmaniasis (VL) is an infectious disease caused by the protozoan parasite Leishmania (Leishmania) infantum, an intracytoplasmic parasite that affects humans and other species of domestic and wild mammals. In Brazil, the treatment of canine visceral leishmaniasis (CVL) with miltefosine has been implemented since 2016, and the reports on the clinical and immunological conditions of treated dogs are scarce. Thus, this study aimed to assess and monitor the clinical, laboratory, and immunological condition of dogs with CVL before (D) and after (D) using three pharmacotherapeutic protocols: miltefosine monotherapy (Milteforan™, Virbac) (G1), miltefosine plus allopurinol (G2), and allopurinol monotherapy (G3).

Canine visceral leishmaniasis: perception, prevalence, and spatial distribution in municipality of Nossa Senhora do Livramento, Mato Grosso, Brazil.

The midwest region of Brazil has witnessed an increase in the number of cases of human (HVL) and canine visceral leishmaniasis (CVL). The aim of the present study was to evaluate the population's perception of these diseases, factors associated with CVL, its spatial distribution, and the prevalence of anti-Leishmania spp. in 385 dogs, determined using a commercially available immunochromatographic rapid test and confirmed using enzyme-linked immunosorbent assay (ELISA).